Ariad Pharmaceutical (NASDAQ: ARIA)‘s stock had its “outperform” rating reaffirmed by research analysts at Rodman & Renshaw in a report issued on Wednesday. They currently have a $18.00 price target on the stock.
Separately, analysts at Bank of America (NYSE: BAC) reiterated a “neutral” rating on shares of Ariad Pharmaceutical in a research note to investors on Monday, December 12nd. They now have a $14.00 price target on the stock. Analysts at JPMorgan Chase & Co. (NYSE: JPM) reiterated an “overweight” rating on shares of Ariad Pharmaceutical in a research note to investors on Monday, December 12nd. Also, analysts at Jefferies Group (NYSE: JEF) reiterated a “buy” rating on shares of Ariad Pharmaceutical in a research note to investors on Monday, December 12nd.
ARIAD Pharmaceuticals, Inc. (ARIAD) is a biopharmaceutical company focused on the discovery and development of drugs to provide therapeutic intervention in treating human diseases at the cellular level. The Company’s lead cancer product candidate, ridaforolimus, is an internally discovered, potent inhibitor of the protein mTOR. mTOR acts as a central regulator of protein synthesis, cell proliferation, cell cycle progression and cell survival. Its second product candidate, AP24534, is an investigational, pan BCR-ABL inhibitor that has potential applications in various hematological cancers and solid tumors and is wholly owned by the Company. Its third product candidate, AP26113, is an investigational anaplastic lymphoma kinase (ALK), inhibitor that has the potential to regulate multiple cancer pathways and to be used in the treatment of certain patients with various cancers, including non-small cell lung cancer, lymphoma and neuroblastoma.
Shares of Ariad Pharmaceutical traded up 2.47% during mid-day trading on Wednesday, hitting $14.11. Ariad Pharmaceutical has a 52 week low of $5.06 and a 52 week high of $14.06. The stock’s 50-day moving average is $11.86 and its 200-day moving average is $10.82. The company has a market cap of $1.875 billion.